{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:11:23Z","timestamp":1794557483196,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Dutch Pharmacists Association","id":[{"id":"https:\/\/ror.org\/00gdw7f12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41431-023-01347-3","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T04:04:25Z","timestamp":1680235465000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics"],"prefix":"10.1038","volume":"32","author":[{"given":"Lianne","family":"Beunk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-6867","authenticated-orcid":false,"given":"Marga","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Soree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke J.","family":"de Boer-Veger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-7266","authenticated-orcid":false,"given":"Elisa J. F.","family":"Houwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Risselada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A. P. J. M.","family":"Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-9924","authenticated-orcid":false,"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H. M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van der Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"1347_CR1","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1371\/journal.pmed.0040209","volume":"4","author":"JJ Swen","year":"2007","unstructured":"Swen JJ, Huizinga TW, Gelderblom H, de Vries EGE, Assendelft WJJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209.","journal-title":"PLoS Med"},{"key":"1347_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","volume":"11","author":"R van Westrhenen","year":"2020","unstructured":"van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Juki\u0107 MM. Pharmacogenomics of antidepressant and antipsychotic treatment: How far have we got and where are we going? Front Psychiatry. 2020;11:94.","journal-title":"Front Psychiatry"},{"key":"1347_CR3","doi-asserted-by":"publisher","first-page":"725565","DOI":"10.3389\/fphar.2021.725565","volume":"12","author":"R van Westrhenen","year":"2021","unstructured":"van Westrhenen R, Ingelman-Sundberg M. Editorial: from trial and error to individualised pharmacogenomics-based pharmacotherapy in psychiatry. Front Pharmacol. 2021;12:725565.","journal-title":"Front Pharmacol"},{"key":"1347_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","volume":"83","author":"JJ Swen","year":"2008","unstructured":"Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharm Ther. 2008;83:781\u20137.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharm Ther. 2011;89:662\u201373.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41397-019-0105-1","volume":"19","author":"LA Marcath","year":"2019","unstructured":"Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J. 2019;19:501\u201315.","journal-title":"Pharmacogenomics J"},{"key":"1347_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41431-018-0205-4","volume":"26","author":"H-J Guchelaar","year":"2018","unstructured":"Guchelaar H-J. Pharmacogenomics, a novel section in the European Journal of Human Genetics. Eur J Hum Genet. 2018;26:1399\u2013400.","journal-title":"Eur J Hum Genet"},{"key":"1347_CR8","doi-asserted-by":"crossref","unstructured":"Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk A-M, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021;30:1105\u201313.","DOI":"10.1038\/s41431-021-00920-y"},{"key":"1347_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116\u201324.","journal-title":"Clin Transl Sci"},{"key":"1347_CR10","unstructured":"CYP3A4 cytochrome P450 family 3 subfamily A member 4 [Homo sapiens (human)] [Internet]. National Center for Biotechnology Information. [cited 2021 Nov 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/1576."},{"key":"1347_CR11","unstructured":"CYP3A4 cytochrome P450 family 3 subfamily A member 4 [Internet]. Genome Aggregation Database. [cited 2021 Nov 9]. Available from: https:\/\/gnomad.broadinstitute.org\/gene\/ENSG00000160868?dataset=gnomad_r2_1."},{"key":"1347_CR12","unstructured":"CYP3A4 [Internet]. Pharmacogene Variation Consortium. [cited 2021 Nov 9]. Available from: https:\/\/www.pharmvar.org\/gene\/CYP3A4."},{"key":"1347_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274\u201386.","journal-title":"Pharmacogenomics J"},{"key":"1347_CR14","unstructured":"Annotation of RNPGx Guideline for tacrolimus and CYP3A4, CYP3A5 [Internet]. PharmGKB. [cited 2022 Dec 14]. Available from: https:\/\/www.pharmgkb.org\/chemical\/PA451578\/guidelineAnnotation\/PA166202481."},{"key":"1347_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1086\/426406","volume":"75","author":"EE Thompson","year":"2004","unstructured":"Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004;75:1059\u201369.","journal-title":"Am J Hum Genet"},{"key":"1347_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FPC.0b013e328351f3c1","volume":"22","author":"L Elens","year":"2012","unstructured":"Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RHN. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22:373\u201380.","journal-title":"Pharmacogenet Genomics"},{"key":"1347_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","volume":"21","author":"L Elens","year":"2011","unstructured":"Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011;21:861\u20136.","journal-title":"Pharmacogenet Genomics"},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JCP.0000000000000070","volume":"34","author":"K van der Weide","year":"2014","unstructured":"van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol. 2014;34:256\u201360.","journal-title":"J Clin Psychopharmacol"},{"key":"1347_CR19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","volume":"57","author":"L Elens","year":"2011","unstructured":"Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574\u201383.","journal-title":"Clin Chem"},{"key":"1347_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/1078-0432.CCR-14-1758","volume":"21","author":"M Apell\u00e1niz-Ruiz","year":"2015","unstructured":"Apell\u00e1niz-Ruiz M, Lee M-Y, S\u00e1nchez-Barroso L, Guti\u00e9rrez-Guti\u00e9rrez G, Calvo I, Garc\u00eda-Est\u00e9vez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin cancer Res. 2015;21:322\u20138.","journal-title":"Clin cancer Res"},{"key":"1347_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","volume":"12","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12:121\u201332.","journal-title":"Pharmacogenetics"},{"key":"1347_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clpt.2006.04.012","volume":"80","author":"Y Nakajima","year":"2006","unstructured":"Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharm Ther. 2006;80:179\u201391.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharm Ther. 2017;102:688\u2013700.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR24","unstructured":"CYP1A2 cytochrome P450 family 1 subfamily A member 2 [Homo sapiens (human)] [Internet]. National Center for Biotechnology Information. [cited 2021 Nov 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/1544."},{"key":"1347_CR25","unstructured":"CYP1A2 cytochrome P450 family 1 subfamily A member 2 [Internet]. Genome Aggregation Database. [cited 2021 Nov 9]. Available from: https:\/\/gnomad.broadinstitute.org\/gene\/ENSG00000140505?dataset=gnomad_r2_1."},{"key":"1347_CR26","unstructured":"CYP1A2 allele nomenclature [Internet]. Pharmacogene Variation Consortium. [cited 2021 Nov 9]. Available from: https:\/\/www.pharmvar.org\/gene\/CYP1A2."},{"key":"1347_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1046\/j.1365-2125.2002.01673.x","volume":"54","author":"A Nordmark","year":"2002","unstructured":"Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharm. 2002;54:504\u201310.","journal-title":"Br J Clin Pharm"},{"key":"1347_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1124\/mol.64.3.659","volume":"64","author":"E Aklillu","year":"2003","unstructured":"Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharm. 2003;64:659\u201369.","journal-title":"Mol Pharm"},{"key":"1347_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00228-005-0057-z","volume":"62","author":"K Takata","year":"2006","unstructured":"Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharm. 2006;62:23\u20138.","journal-title":"Eur J Clin Pharm"},{"key":"1347_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1517\/17425255.2012.657626","volume":"8","author":"J McGraw","year":"2012","unstructured":"McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8:371\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1347_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2133\/dmpk.20.24","volume":"20","author":"A Soyama","year":"2005","unstructured":"Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet. 2005;20:24\u201333.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1347_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1258\/0004563053857798","volume":"42","author":"JE Kootstra-Ros","year":"2005","unstructured":"Kootstra-Ros JE, Smallegoor W, van der Weide J. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem. 2005;42:216\u20139.","journal-title":"Ann Clin Biochem"},{"key":"1347_CR33","first-page":"163","volume":"7","author":"NMG Looman","year":"2013","unstructured":"Looman NMG, Matic M, Mulder H, Van Hulst R, Van Schaik RHN, Bruggeman R. Associatie van genetische variatie in CYP1A2 en UCT1A4 met metabole stoornissen bij gebruikers van clozapine en olanzapine [Association of genetic variation in CYP1A2 and UGT1A4 with metabolic disorders in users of clozapine and olanzapine]. Pharm Weekbl. 2013;7:163\u20136.","journal-title":"Pharm Weekbl"},{"key":"1347_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharm Ther. 2021;110:563\u201372.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nrd3921","volume":"12","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Disco. 2013;12:3\u20134.","journal-title":"Nat Rev Drug Disco"},{"key":"1347_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cpt.1049","volume":"103","author":"JJ Swen","year":"2018","unstructured":"Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk A-M, Houwink EJF, et al. Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharm Ther. 2018;103:795\u2013801.","journal-title":"Clin Pharm Ther"},{"key":"1347_CR37","unstructured":"Prioritization of CPIC guidelines [Internet]. Clinical Pharmacogenetics Implementation Consortium. [cited 2021 Nov 9]. Available from: https:\/\/cpicpgx.org\/prioritization-of-cpic-guidelines\/."},{"key":"1347_CR38","unstructured":"U.S. Food and Drug Association (FDA). Table of pharmacogenetic associations [Internet]. [cited 2022 Mar 1]. Available from: https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-023-01347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-023-01347-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-023-01347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:03:00Z","timestamp":1710136980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-023-01347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1038\/s41431-023-01347-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research involves a literature study and no human subjects, human material, or human data. Therefore, no approval by an ethics committee was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}